BTIG Research initiated coverage on Mustang Bio with a new price target
$MBIO
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research initiated coverage of Mustang Bio with a rating of Buy and set a new price target of $11.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/24/2022 | $13.00 → $6.00 | Buy | B. Riley Securities |
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1). On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation ("AbbVie"), for $1.0 million. Mustang has relocated its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts. Mustang expects to continue to rely on its academic part
WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing. In addition, as a result of the closing of the public offering announced by the Company on February 10, 2025, the Company believes that it has a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market as required by Nasdaq Listing Rule 5550(b)(1). The Company is awaiting a formal compliance determin
B. Riley Securities reiterated coverage of Mustang Bio with a rating of Buy and set a new price target of $6.00 from $13.00 previously
BTIG Research initiated coverage of Mustang Bio with a rating of Buy and set a new price target of $11.00